Loading...
XHEL
ORNAV
Market cap7.78bUSD
Apr 11, Last price  
47.59EUR
1D
-2.02%
1Q
6.11%
Jan 2017
12.29%
IPO
244.86%
Name

Orion Oyj

Chart & Performance

D1W1MN
P/E
20.61
P/S
4.41
EPS
2.31
Div Yield, %
3.40%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
7.98%
Revenues
1.54b
+29.66%
1,901,800,000311,200,000683,600,000710,700,000771,500,000849,900,000917,900,000980,300,0001,006,900,0001,015,300,0001,015,600,0001,073,500,0001,084,700,000977,400,0001,050,900,0001,078,100,0001,041,000,0001,340,700,0001,189,600,0001,542,400,000
Net income
330m
+52.17%
131,100,00066,600,000145,400,000136,300,000151,400,000184,700,000209,500,000208,900,000206,200,000211,300,000208,200,000249,000,000226,000,000330,300,000200,400,000219,900,000193,800,000349,500,000216,800,000329,900,000
CFO
293m
+146.55%
173,300,00081,600,000150,900,000144,400,000204,600,000209,100,000198,900,000221,000,000215,200,000296,700,000254,900,000249,100,000228,400,000230,900,000270,800,000299,100,000215,700,000434,400,000119,000,000293,400,000
Dividend
Oct 15, 20240.81 EUR/sh
Earnings
Apr 23, 2025

Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
URL
https://www.orion.fi/
IPO date
Jul 03, 2006
Employees
3,657
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,542,400
29.66%
1,189,600
-11.27%
1,340,700
28.79%
Cost of revenue
1,135,400
958,400
906,600
Unusual Expense (Income)
NOPBT
407,000
231,200
434,100
NOPBT Margin
26.39%
19.44%
32.38%
Operating Taxes
83,200
55,100
90,800
Tax Rate
20.44%
23.83%
20.92%
NOPAT
323,800
176,100
343,300
Net income
329,900
52.17%
216,800
-37.97%
349,500
80.34%
Dividends
(228,000)
(224,900)
(211,200)
Dividend yield
3.79%
4.08%
2.93%
Proceeds from repurchase of equity
(17,900)
BB yield
0.25%
Debt
Debt current
29,000
17,200
Long-term debt
179,100
204,900
Deferred revenue
66,900
68,700
Other long-term liabilities
314,900
14,000
12,300
Net debt
(205,600)
101,100
(111,800)
Cash flow
Cash from operating activities
293,400
119,000
434,400
CAPEX
(62,300)
(65,600)
(73,100)
Cash from investing activities
(85,200)
(108,400)
(154,300)
Cash from financing activities
(108,800)
(243,200)
(159,800)
FCF
252,300
(6,000)
233,200
Balance
Cash
205,600
106,700
332,600
Long term investments
300
1,300
Excess cash
128,480
47,520
266,865
Stockholders' equity
1,010,400
902,200
942,900
Invested Capital
1,191,420
1,123,480
928,935
ROIC
27.98%
17.16%
42.63%
ROCE
30.02%
19.22%
35.06%
EV
Common stock shares outstanding
140,533
140,361
140,590
Price
42.78
8.88%
39.29
-23.32%
51.24
40.31%
Market cap
6,011,987
9.02%
5,514,785
-23.45%
7,203,832
40.35%
EV
5,806,387
5,615,885
7,092,032
EBITDA
407,000
282,700
481,600
EV/EBITDA
14.27
19.87
14.73
Interest
3,500
5,700
1,500
Interest/NOPBT
0.86%
2.47%
0.35%